Identification of drug candidate Service

OVERVIEW

It is about 8 weeks t develop Fast-MAb monoclonal antibody, produce and purify with HuProt™ microarray vertification.

Customer report and evaluation are 4 stages according to milestones which are transferred in each stages.

Invoice issuing starts at beginning of 1st stage and end of each stages.
Milestone means potential terminal goal if expected result doesn’t meet with satisfaction or according to requirement.

PROJECT SPECIFICATION

Antigen design, vaccination strategy and screening method is important to achieve High value added goal.
CDI can completely customize developing process to fulfill requirement and to offer estimate based on output product.

SERVICE STEPS

PHASE 1 >> ANTIGEN AND IMMUNIZATION

We use 5 mouse immunization using 0.5-2mg client provided protein or carrier-peptide with 80% purity protein.

Or help antigen design or synthesis with CDI.

CDI include 21,000 human protein library.

PHASE 2 >> FUSION AND SCREENING

Select 2 most reactive subjects and collect immune cells to fuse with myeloma producing several hybridoma.

Screening supernatant fluid of IgG-secreting clone.

PHASE 3 >> SUB-CLONING AND EXPANSION

High quality clones (5~30) are selected to be subclone.

Enlarge them to 23 well plate each, and enlarge to T-25 flask.

Supernatant fluid is delivered for additional customer evaluation.

PHASE 4 >> PRODUCTION, PURIFICATION, QA

Each clones are bottled up, labeled and frozen. Each samples are kept for Mycoplasma test.

Produce in 3 kinds of clone according to requirement.

Evaluate with CDI HuProt™ Human Proteome Microarray. V4.0 after purifying produced antibody.

DELIVERABLES

Detail specific date and additional QA document are ready.

Purified antibody and whole frozen clones are delivered to customer.

단백질칩, 단백질 칩, 바이오칩, 바이오 칩, 마이크로어레이, 마이크로 어레이, 프로틴 칩, 프로틴칩, Protein chip, Proteinchip, BioChip, Bio chip, 단백질 마이크로 어레이, DNA 마이크로 어레이, MicroArray, Micro Array, Protein microarray, protein micro array